Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
Gillette
Archived
•
August 10, 2026
•
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML
Source: Gillette News Record | https://www.gillettenewsrecord.com/search/?f=rss&t=article&l=50&s=start_time&sd=desc - Read Original
"Free Quote Today"
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!
Sponsored
"Retirement Health Care"
"Output is a realization of Input."